Thatiane De Oliveira Sergio
Raizel M. Frasier
Frederic W. Hopf- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States
Alcohol Use Disorder (AUD) ranks among the most prevalent mental disorders, extracting ~$250 billion/year in the US alone and producing myriad medical and social harms. Also, the number of deaths related to problem drinking has been increasing dramatically. Compulsive alcohol drinking, characterized by intake that persists despite negative consequences, can be particularly important and a major obstacle to treatment. With the number of people suffering from AUD increasing during the past years, there is a critical need to understand the neurobiology related to compulsive drives for alcohol, as well as the development of novel AUD pharmacological therapies. Here we discuss rodent compulsion-like alcohol drinking (CLAD) models, focusing on the two most widely used adverse stimuli to model rodent compulsion-like responding, quinine adulteration of alcohol and footshook-resistant alcohol intake. For both cases, the goal is to uncover behavior patterns and brain circuits that underlie drive for alcohol even in the face of negative consequences. We discuss caveats, benefits, and potential brain mechanisms, of models for consequence-resistant responding for alcohol more generally, and especially highlight some advantages of quinine-resistance over footshook-resistance. Further, since this review contributes to a Special issue focused on Molecular Aspects of Compulsive Drug Use, we discuss our new findings showing how the noradrenergic system is related to CLAD responding. In particular, we comment on the importance of α1 and β adrenergic receptors (ARs) as potential targets for treating AUD.
1. Introduction
Alcohol consumption occurs widely in numerous cultural and social events, and, although it provides pleasure to many, a subset of people move from recreational use to development of drinking problems (1–4). Indeed, misuse of alcohol relates to many negative personal and social outcomes, which overall occur in high frequency (e.g., vehicle crashes, falls, sexually transmitted diseases, unintended or poor pregnancy outcomes, high blood pressure, cholesterol, heart and liver diseases), and costs a substantial amount of money worldwide from health care expenditures, lost work productivity, criminal justice, etc., (1, 5–11). In the United States alone, excessive alcohol use in 2010–2011 was responsible for ~95,000 deaths and ~$249 billion, or $2.05 per drink, and binge drinking accounted for 77% of these costs, or $191 billion (1). Also, in the European Union, alcohol ranks as the most harmful abused drug, followed by heroin and crack (12). Indeed, because alcohol is legal, it continues to extract outsized costs relative to other intoxicants.
More recent findings remain discouraging. A recent study found that excessive alcohol drinking is now the leading cause of death in young to middle-aged U.S. adults, accounting for 1 in 5 deaths among adults aged 20 to 49 years, and 1 in 8 deaths among adults aged 20 to 64 years (13). Also, these alarming findings can still be conservative, given that they are based on deaths related to alcohol conditions that were more clearly identified. It is also important to point out that this study examined excessive drinking levels before the COVID-19 pandemic, which itself has increased problem drinking as much as 30% (14–16). However, one cause for some hope is that alcohol intake in high school students has steadily dropped since the year 2000 or so1. Despite the alarming scale of alcohol drinking problems, only a few pharmacological compounds are approved for treatment (17, 18), and much remains unclear about the complexity of the neural and molecular mechanisms related to this disease.
We are particularly interested in compulsion-like responding for alcohol, where intake persists despite negative consequences, since this can be a major obstacle to treatment and a strong driver of excessive intake (3, 19–27). Also, problem drinking in women has risen dramatically in recent years (2, 28–30), and women often suffer greater consequences from their alcohol use (31–33). Furthermore, negative affect and anxiety-related conditions can strongly contribute to alcohol drinking (4, 34–38), at least in some individuals (39–42), and women have nearly twice the risk of developing an affect disorder (43–48) and have higher comorbidity of AUD and affect disorders (32, 35). Thus, to help develop better, personalized therapies (40), it is essential to understand sex differences and similarities in mechanisms underlying excessive drinking and its comorbidities (37, 38, 49).
It is also important to note that compulsion-like motivations are just one of several important drivers of problem alcohol drinking. For example, human studies have long examined possible mechanistic differences in so-called reward vs. relief drinking (39–42). Reward drives include alcohol cue reactivity, sensation-seeking, and impulsivity, and can be assessed by self-reported subjective stimulation and intoxication by alcohol. Relief drinking is focused on intake to relieve or stave off negative emotional or physical feelings. Like many other mental health conditions, there are conditioned cues, in our case for alcohol, that can strongly and more automatically elicit approach toward such alcohol cues (50–53) [see also Weafer et al. (54)]. In addition, these are not the only factors that can drive alcohol-directed behavior, and it is likely that a given problem drinker can exhibit different motives for alcohol at different times, or some combination of drives. Nonetheless, more automatic and reflexive responding has been considered an important aspect of compulsion-like drinking (3, 27, 55–57). In addition, groups have emphasized the fundamental role of conflict for compulsive aspects of addiction (19, 22, 58) (discussed in Section 2), as well as high motivation, reflected in part by continuation of responding despite the cost of dealing with negative consequences (3, 27).
Other aspects of compulsion, including considerations and caveats, are discussed in several recent reviews (59–63), and we predominantly agree with the points they detail in our publications (64–70). These include (1) considerations of over-focus on compulsion, to the detriment of overlooking other factors that can contribute to addiction (59–61, 65, 71) (above), (2) the importance of considering compulsion for alcohol when adapting the NIMH RDoC framework for addiction (3, 72, 73), and (3) the importance of agency and knowledge of choosing during recovery from compulsion-like drinking pattern (19, 20, 74, 75).
Finally, in identifying and targeting brain mechanisms thought to drive pathological alcohol drinking, we are particularly interested in identifying whether there might be pharmacotherapies which would be effective against compulsion-like drinking, especially in individuals with higher daily intake levels. This is in alignment with overall shifts in recent decades that recognize the importance of individual differences and personalized medicine.
2. Quinine-resistant drinking: Some advantages over footshock-resistance?
While clinical studies are essential for understanding alcohol drives in humans, they have important limitations, especially in the ability to have mechanistic interventions. Thus, rodent work more generally affords a number of specific and valuable methods to uncover critical aspects of brain circuitry that mediate compulsive drives for alcohol. For example, our group has used projection-specific optogenetic inhibition, using laser light to inhibit projections from specific cortical cells during different aspects of behavior (detailed below), and in vivo recording of brain activity patterns during CLAD and alcohol-only drinking (AOD) (70). Combined with local pharmacological inhibition during drinking, these preclinical interventions can help unravel the molecular and neural mechanisms related to CLAD (and excessive drinking more generally). In addition, as we detail below, behavioral microstructure, combined with other methods, likely provides some important insights into the action strategies rats utilize during different kinds of alcohol drinking, and perhaps even subjective state (discussed below).
2.1. Footshock-resistance as a CLAD model
Maintaining intake in the face of shock (footshock-resistance) is sometimes considered more of a gold standard to model human compulsion, including since shock is well-defined in its ability to evoke fear and as an aversive stimulus (25, 27, 76). Thus, we examined the brain circuitry that might underlie footshock-resistance for alcohol.
It would be especially valuable if we found evidence that a common circuit is important for CLAD across different adverse conditions and even across species. We have argued for the central importance of the Anterior Insula Cortex (AIC) system, which detects and helps respond to high importance situations, for addiction-related states and behaviors [detailed in Centanni et al. (66)], along with other reviews relating AIC to alcohol behaviors (77–79). More generally, AIC is a key regulator of the Salience Network, including medial prefrontal cortex, nucleus accumbens, amygdala, and other areas, which together play a broad role in importance-directed planning and action (66, 80–82). Thus, our projection-specific optogenetic studies (83) focused on rat putative Salience Network areas, and, importantly, we found that inhibiting either (1) AIC-to-nucleus accumbens or (2) medial prefrontal-to-nucleus accumbens significantly reduced footshock-resistant operant responding for alcohol; critically, these pathways have no impact on operant responding for alcohol-only (see below).
Interestingly, Grodin et al. (84) set out to develop a shock-resistant responding for alcohol paradigm in heavy drinking humans, and found a similar AIC/medial prefrontal/striatal circuitry for compulsive action for alcohol. While artificial, a similar AIC system is activated by imagining higher-risk (vs. lower risk) drinking in problem-drinking humans (85). This human-rodent concurrence in underlying brain circuits related to consequence-resistant responding for alcohol has increased our confidence that the rodent CLAD models we and others use may tap into circuits relevant to human consequence-resistant responding for alcohol. We also note that other regions, such as central nucleus of the amygdala, locus coeruleus, and periaqueductal gray, are likely important for compulsion-like aspects of addiction (3, 86–90).
Before addressing quinine, we want to further address the findings described above that AIC projections regulate CLAD but not AOD in rats (83). Similar to our studies in rats, disrupting AIC in male mice decreases CLAD but not AOD (91), and rat studies link AIC to level of CLAD expression (92) (see also Section 4 for orexin and CLAD vs. AOD). Similar, convergent human and rodent evidence implicates NMDARs in more pathological aspects of alcohol drives [detailed in Hopf (26), Simmler et al. (89); Section 4]. We interpret these findings in relation to discussions from clinical groups (22, 58) who propose that compulsion during addiction reflects conflict between desired reward and desire to avoid adverse consequences. Importantly, in this view, it is the conflict that recruits the Salience Network to play a role during compulsive drives for intake (22, 58). This use of AIC signaling to resolve and overcome conflict is a central part of our model, where CLAD involves need for greater attention on acting to obtain the reward, in our case alcohol (detailed below).
2.2. Quinine-resistance as a CLAD model
For alcohol studies, researchers have long tried to address adversity-resistant drive for intake by putting the bitter-tasting adulterant, quinine, into the alcohol. Here, we address some evidence that footshock- and quinine-resistance may be mechanistically related, then discuss several advantages of the quinine-alcohol drinking model.
Our studies described above show that AIC-to-nucleus accumbens and medial prefrontal-to-nucleus accumbens projections are critical for maintaining footshock-resistant alcohol intake, with no role in alcohol-only intake (83). Most importantly, in the same study, both neural projections also significantly promote quinine-resistant alcohol drinking. Thus, AIC-related salience circuits are critical for promoting both quinine-resistant and footshock-resistant alcohol drinking, suggesting a common mechanism, and validating the use of the simpler quinine-resistance model. In agreement, higher shock-resistance and quinine-resistance for alcohol are well correlated in rats (86, 93). Further, NMDA receptor modulators regulate quinine-resistant alcohol intake but not AOD in rats (at moderate doses), and parallel human studies implicate NMDA receptors in alcohol craving and drinking in treatment-seekers (ostensibly in conflict about drinking) but not in non-treatment-seekers [reviewed in Hopf (26) and Wegner et al. (94)]. Together, these results suggest that quinine-resistance in rat recruits a brain mechanism similar to footshock-resistance and perhaps also to human compulsion for alcohol. However, a recent study in genetically-selected, high-alcohol-drinking cHAP mice found much greater quinine resistance relative to shock resistance for alcohol (95). Nonetheless, the long-term, intermittent-access alcohol intake model we and others use in rat (Figure 1) exhibits several other features related to human AUD other than consequence-resistant responding for alcohol, including escalating intake (3, 96), sensitivity to compounds that reduce human drinking (96), withdrawal symptoms (although moderate) (97, 98), and front loading (indicating high motivation for alcohol) (67, 68, 99, 100). Thus, CLAD after long-term drinking in rats potentially reflects aspects of human problem drinking that are recapitulated in footshock-and quinine-resistant alcohol intake models.
Figure 1. Intermittent two-bottle choice, access to alcohol, paradigm. Wistar rats have access to alcohol (20% v/v diluted in water) in the intermittent two-bottle choice paradigm. Briefly, three times a week (starting Monday, Wednesday and Friday around start of the dark cycle), rats have an 18–24 h period where alcohol is available concurrently with water. The alcohol and water bottle positions are alternated across days to prevent a position bias. Intermittent access continues for ~12 weeks, since longer-term intake is necessary to facilitate development of aversion-resistant alcohol intake. After ~3 months of intermittent access, rats are then shifted to Limited Daily Access two-bottle choice, with 20 min access to 20% alcohol or water Monday through Friday. After at least 2–3 wk limited daily access, rats have 2–3 alcohol-quinine sessions per quinine dose used to habituate to the novelty of quinine in alcohol. Experimental testing of quinine-resistant alcohol drinking then begins, typically with 2 test sessions per week.
One major goal of this commentary is to describe what we see as several advantages of quinine compared to footshock for CLAD studies. First, quinine-resistance is technically easier and faster since it does not require extensive daily operant training as in footshock-resistant alcohol drinking. Additionally, with much less personnel labor, quinine-resistance is also cheaper (the only thing necessary is a bottle with alcohol solution adulterated with quinine). We are further impressed with the robust ability to use quinine in alcohol to scale the level of aversion-resistance required to get alcohol. For example, the doses of quinine can be widely manipulated in the same individual rodent, and we frequently test multiple quinine doses per animal (across 10, 60, and 100 mg/L) in longer, randomized studies (67–70) (we consider 10 mg/L moderate-challenge and 60–100 mg/L higher-challenge). In our experience, it is more challenging to test different levels of shock and footshock-resistance in the same rat. In our previous study (83), half of male rats are resistant to alcohol when 1 in 8 responses is paired with shock, while nearly all rats strongly suppress consumption when the stimulus is delivered for 1 in 3 rewards. A similar “self-imposed abstinence” can be seen with ascending shock levels for cocaine (101, 102). We also attempted to do intermittent footshock synched to bottle licking for alcohol, and found our results quite variable (unpublished observations). One challenge with repeated testing of shock across conditions is possible sensitization after earlier shocks (27). However, even with these points, it could still be useful for some mechanistic studies of CLAD to test both quinine-resistance and shock-resistance.
One criticism about the quinine-adulteration model is that rodents could be less sensitive to bitter taste due the exposure of alcohol (59). However, several groups concur that male and female alcohol-drinking rats and mice greatly avoid consuming water adulterated with quinine levels that they will consume when in alcohol (65, 69, 103, 104), indicating robust aversion resistance to obtain alcohol.
2.3. Using quinine-resistant drinking to infer putative subjective states underlying CLAD
Our group has worked to assess different patterns within licking under different alcohol conditions that might give clues to underlying action strategies being used. Importantly, lickometry and microstructural analysis of different licking behaviors has long been used to attempt to provide valuable insights into what type of responding the rat is choosing to engage in. For example, one could argue that compulsion-like drinking reflects a state of higher motivation, since the individual is willing to tolerate cost and adversity to obtain the alcohol. Based on the classic lickometry literature [discussed in Darevsky et al. (67), Darevsky and Hopf (68), and detailed in a concurrently submitted review], we might predict longer and/or faster licking.
In strong contrast with this prediction, we find that licking under aversive but tolerable (moderate) challenge is actually less variable in many lick measures (67, 68). While initially unexpected, more automatic and reflexive responding has been considered an important aspect of compulsion-like responding (3, 27, 55–57) (and identifying decreased variability in CLAD responding is one example of the strengths of microstructural analysis of licking). Moderate-challenge CLAD also shows significantly earlier bout start than AOD, and together we have proposed a Head Down and Push model of challenge-resistant responding. In particular, we propose that less variable responding reflects the putative goals of (1) focusing internal attention more on automatic action, and (2) ignoring negative consequences as best as possible, which would be helped by maintaining attentional control on performing the action; these are in contrast to the putatively cognitively simpler alcohol-only drinking (Figures 2A, B) (67, 68). Under higher-challenge alcohol drinking, total intake is greatly reduced (~40–50%), and lick timing becomes more variable and disrupted (the opposite of moderate-challenge). Interestingly, however, higher-challenge retains the better tongue control and earlier bout start seen with moderate-challenge (and which is different from alcohol-only) (Figure 2C), despite overall deficits in responding. Tongue control, attentional control, and overall action plans are likely strongly regulated by AIC (66–68). Thus, we consider these findings to indicate that AIC commitment to aversion-resistant alcohol intake remains strong under higher challenge [which was also observed in AIC firing patterns during CLAD; (70)]. In contrast, as we detail in another currently submitted review, we consider it likely that reduced intake and action organization under higher challenge is to due disruptions in medial prefrontal cortex activity [discussed in Darevsky et al. (67) and Darevsky and Hopf (68)].
Figure 2. Somewhat anthropomorphized representations of proposed action, attention, and emotion regulation strategies utilized, including internal mental emotional states, during different rat drinking conditions. (A) Easy, alcohol-only drinking, with no overt adverse challenge. Several clinical groups propose that unchallenged intake recruits a more striatal circuit (22, 58), with less cortical role. (B) Drinking alcohol despite bad but tolerable challenge. Challenged rats show less variable responding in nearly every licking measure, including better control of tongue shape, relative to alcohol-only in (A). This is consistent with focusing on making more automatic, stereotyped actions. At the same time, we have proposed that the rat works to not put attention on the bad consequences (i.e., it successfully distracts itself); together, we call these the Head Down and Push model of responding despite challenge. (C) Drinking alcohol despite quite high challenge (enough to drop drinking by almost half). We propose that higher-challenge CLAD reflects Intake Defense: an idea that came from need to eat some food, even if it is spoiled [discussed in Darevsky et al. (67), Darevsky and Hopf (68) and Kaplan et al. (105)]. The goal is to just start, and push to get “enough” intake. Interestingly, high challenge drinking still shows better tongue control, and early initiation of drinking bouts. Since overall action plan, attentional regulation, and tongue control are all strongly regulated by the AIC, and lick measures can be observed under both high challenge (C) and less bad challenge (B), we suggest that AIC's “commitment to act” is strongly maintained under high challenge; we propose that higher-challenge intake fails due to dis-coherence in the dorsal medial prefrontal cortex: see Darevsky et al. (67) and Darevsky and Hopf (68) and De Oliveira Sergio et al. (submitted) for further discussion.
We also would like to emphasize the purpose of our attempts to the infer both the action strategy utilized and also the subjective state of the rat under different drinking conditions. For example, along with the substantial AIC literature [reviewed in Centanni et al. (66)], we believe that the reduced variability in responding during moderate-challenge CLAD reflects a need for increased attentional control (focus on action to help decrease awareness of negative consequences). Such inferences about internal, subjective, and emotional states, if they are warranted by robust evidence, can be valuable in trying to understand the action (and likely emotion regulation) strategy that an individual is using under a given drinking condition. Importantly, we are in no way attempting to make light of AUD through our use of more colloquial language when attempting to describe the putative subjective state of the rodent. Our central goal is to understand the brain and psychological mechanisms of compulsion-like drives for alcohol (compared with alcohol-only), and using a more anthropomorphic description of particular inferred mental/emotional states is intended to be a pedagogical tool, however speculative, to help “get where the rat (or person) is coming from.” Indeed, others before us [e.g., Sanchis-Segura and Spanagel (106) and Meinhardt and Sommer (107)] have already made cartoon versions of different excessive alcohol drinking states, which were widely distributed, for use in both scientific and public talks. Their goal, as is ours, is both scientific (understanding the specific psychological drives that promote alcohol drinking) and educational, helping other scientists and even the lay public better understand addiction mechanisms, with the goal of increasing therapy development and implementation.
2.4. Using quinine-resistant drinking to assess development of CLAD
As another example of the utility of quinine-resistance, several interesting studies have used quinine-resistance to examine how long alcohol drinking must occur to develop compulsion-like motivation for alcohol. We find that Wistar rats need at least 3 months of intermittent-access alcohol (IAA, 24hr/day 3d/week) to develop CLAD (83, 108, 109), although the alcohol intake is the same on 1.5 and 3 months (96, 108). In contrast, Wistar rats exposed to continuous-alcohol access (CAA) schedule for the same number of months do not develop CLAD (108). Interestingly, a subset Lister Hooded rats also require 3 or more months of IAA to develop CLAD (110, 111), with no CLAD development with CAA (110). Further, genetically-selected, alcohol-preferring Marchigian Sardinian P-rats develop quinine-resistance faster than Wistars and Listar Hooded rats, developing CLAD after 1-2 months of IAA but not CAA (112). However, a recent study found that male and female Indiana alcohol-preferring P-rats develop CLAD, with quite high levels of quinine, within 1 week of alcohol drinking (104). Interestingly, P-rat alcohol intake is significantly reduced by quinine the 1st day of consumption (104), suggesting that only brief drinking history is needed for this line of alcohol-preferring rat to develop compulsion for alcohol. However, while Indiana P-rats tolerate 400 mg/L quinine in alcohol after 1 week of drinking, it takes 3–5 weeks of drinking for males to tolerate even higher quinine (500 mg/L), which females won't tolerate. In addition, this rapid development of CLAD in Indiana P-rats (104) is more similar to what is seen with C57 mice, a commonly used line in alcohol studies because of its intake greater than binge level, where we (113) and others (91, 114) find that C57 mice develop CLAD within a few days of alcohol-only drinking. However, it is important to note that these high-drinking P-rat and C57 still have some ability to choose in their CLAD behavior. For example, given a choice between non-adulterated alcohol solution and quinine-adulterated alcohol, Indiana P-rats choose the alcohol-only, suggesting that they still sense the quinine and find this concentration of quinine aversive (115, 116) [also seen in outbred rats (117)]. Similarly, C57 mice will choose alcohol-only over quinine-alcohol after 2 weeks of drinking (called “inflexible”), although by 8 weeks C57 mice are “indifferent” since they drink as much quinine-alcohol as alcohol-only, even though each are freely available (114). See also Pelloux et al. (118) for AIC and quicker onset of cocaine compulsion (88). For some of these studies (including ours), the ability to repeatedly test quinine-resistance across time in the same individual (in a randomized manner) allows critical within-subject comparisons.
3. Sex differences in compulsion-like alcohol drinking
Problem drinking and AUD in women has risen dramatically in recent years (2, 28–30). In addition, studies show that women can develop problems related to alcohol misuse sooner and at lower drinking amounts than men, which could involve multiple reasons including social and cultural factors as well as biological contributors, such differences in alcohol pharmacokinetics, levels of sex hormones, and effects of alcohol in the brain (31, 33, 37). However, while clinical studies are extremely valuable for understanding the human condition, it is challenging to disentangle biological and social factors in humans, and thus animal tests have potential to provide valuable insights.
Rodent work often finds that females drink more alcohol than males (65), and there have been some mixed findings regarding sex differences in CLAD [reviewed in Radke et al. (65)]. When drinking under two-bottle choice, female and male C57 mice have similar quinine-resistance across quinine doses (103), which we also observe in rats (69). One important caveat is that understanding aversion-resistance requires that changes in drinking with adverse consequences is normalized to the level of alcohol-only drinking within each individual rodent. With such comparisons, it is thus particularly interesting that, under operant conditions (lever pressing to get alcohol), female C57 mice continue responding for alcohol adulterated with higher concentrations of quinine than males (119). Also, a recent study in the genetically-selected, alcohol-preferring cHAP mouse line found that, when alcohol was paired with 0.25 mA footshock, both female and male mice continue responding for alcohol; however, when the shock increased to 0.35 mA only females keep responding (95). On the other hand, in the genetically-selected, alcohol-preferring Indiana P-rat, females and males overall tolerate high levels of quinine, with males tolerating the higher doses more than females (104). Furthermore, several factors could contribute to lack of sex differences under “simpler” (bottle drinking) vs. more complex (or perhaps less ethological) behaviors such as lever pressing. One interesting possibility is that females focus more on specific, high-value aspects of a task, and less on contextual factors, as recently shown for alcohol (120). In this regard, our recent work with anxiety-like behavior (121), along with other studies [e.g., Olvera-Hernandez and Fernandez-Guasti (122) and Shepherd et al. (123)], suggest that females have a particular focus on more life-relevant aspects of a situation. For example, when a food-restricted rat is in a large arena with food under a bright light, female anxiety-like responding is significantly greater for actual contact with food, with no sex differences in anxiety-like responding a few inches away (in the light but not yet contacting food) (121). It is important to note that, although females can show greater quinine- and footshock-resistance for alcohol, there are no sex differences in (highly reduced) consumption of quinine in water, or in more basic sensitivity to shock (65, 69, 95, 119, 122).
In a recent study from our lab (69), we set out to test the hypothesis that females and males might have different internal action strategies when drinking alcohol. Thus, we analyzed the microstructure of licking in female and male rats and found that female and male licking patterns were overall similar in many aspects, except where females had significantly and substantially (~40%) longer bouts than males. There were both important similarities and differences in sex differences in underlying strategies for obtaining alcohol. More generally, females drank more than males under alcohol-only, moderate-challenge and higher-challenge conditions. However, females had similar total licking as males, suggesting an overall difference in licking efficiency (higher volume per lick in females). Importantly, as noted above, females had significantly longer bouts for AOD and AQ10 compared to males, although this was lost under higher challenge. Interestingly, more persistent responding (longer bouts) is often accompanied by faster licking [see Darevsky et al. (67) and Darevsky and Hopf (68)], and males that licked faster did have longer bouts. However, in strong contrast, females could lick slower or faster and still had significantly longer responding. While unexpected, we have taken these differences to indicate that females can have greater persistence-like responding than males, which does not reflect greater vigor per se, and with different strategies under lower vs. higher challenge.
Taken together, these studies suggest that females can have greater levels of consequence-resistant responding for alcohol, although under some (perhaps simpler) conditions there are no sex differences in consequence-resistant responding for alcohol. Finally, these studies suggest that females can use quite different strategies for licking than males, which varies depending on the level of challenge.
4. New insights about the neuropharmacology of quinine-adulterated alcohol intake?
In seeking the neural mechanisms that drive compulsion, and also to shed light on novel treatment options for AUD, the Hopf Lab has focused on how CLAD (and other forms of alcohol drinking), might be regulated by orexin-1-receptors (Ox1Rs) [see Radke et al. (65) and Kwok et al. (124)], AMPA-type glutamate receptors (AMPARs) [see Radke et al. (65), Kwok et al. (124) and Hopf and Mangieri (125)], NMDA-type glutamate receptors [NMDARs, see Hopf (26), Wegner et al. (94) and Seif et al. (109)], and α1 and β adrenergic receptors (126, 127). As most of our findings with Ox1Rs, AMPARs, and NMDARs have been previously reviewed elsewhere, we will focus mainly on our newest findings with noradrenergic signaling (with some contrasts to previous results).
The noradrenergic system regulates arousal, stress responses and alcohol addiction (128, 129). Indeed, several human trials have provided compelling evidence for the efficacy of adrenergic receptors to reduce alcohol craving and drives in heavy drinkers. The α1 adrenergic receptor antagonist prazosin is effective against AUD primarily in those with higher alcohol craving and anxiety during withdrawal (130). In addition, prazosin, and a related compound doxazosin, are more effective against alcohol and stress in those with higher blood pressure (131–133), although others have not seen this (134, 135). Prazosin also modulates alcohol drives and negative affect, stress-cue and alcohol-cue activation, and some aspects of autonomic regulation related to alcohol (132, 136–141).
We find that systemic administration of prazosin at the doses of 1.5 and 0.75 mg/kg decreases AOD and CLAD in male rats (127). Also, prazosin (0.3 μg) directly into AIC, an important regulator of the alcohol compulsion in rodents and humans [detailed above, reviewed in Centanni et al. (66)], also significantly decreases both AOD and CLAD without affecting the saccharin intake (127). Interestingly, inhibition of the projection from AIC to the locus coeruleus area in the brainstem, a major source of noradrenaline for the brain, significantly and strongly reduces CLAD, but has no effect on AOD or saccharin intake (127). This is similar to what we observed when inhibiting AIC projections to the nucleus accumbens, which reduces CLAD but not AOD or sweet fluid intake (83). Since AIC projections are linked specifically to CLAD (and not AOD), it was unexpected for prazosin injected within the AIC to inhibit AOD as well as CLAD. Further studies found that global inhibition of AIC with GABA receptor agonists also strongly reduce both AOD and CLAD (but not saccharin intake), indicating that an AIC signaling pathway other than the ones examined thus far (to nucleus accumbens, to locus coeruleus area) is critical for AOD (127). However, while mPFC can contribute to CLAD (83, 109, 115, 142), we found that injection of prazosin into mPFC did not change CLAD or AUD (126).
Although our findings with prazosin do not show specificity to CLAD or AOD (127), we previously demonstrated that lower doses of the Ox1R blocker SB-334867 decreases CLAD in male and female mice (124, 143), while we (124) and others (144) find that higher doses of inhibitor are needed to reduce AOD. Ox1R agents are thus being considered for human addiction treatment [discussed in Giannotti et al. (145)]. In addition, in heavy human drinkers, the NMDAR blocker memantine impacts craving but not simple alcohol intake (146), part of a set of findings, suggesting that a non-canonical NMDAR is linked in rodents and humans to more pathological aspects of alcohol addiction [discussed in Hopf (26)]. As such, we examined systemic administration of D-serine, a canonical positive modulator of NMDARs at the glycine site, with potential for moderate NMDAR regulation. D-serine (300 mg/kg) decreases CLAD but not AOD (although higher D-serine reduces both CLAD and AOD) [(109); see also Wegner et al. (94)]. Surprisingly, we found that injection of D-serine into the nucleus accumbens suppresses CLAD but not AOD, and the canonical NMDAR inhibitor AP5 shows the same behaviorally selective effects, suggesting that D-serine is inhibiting NMDARs to reduce CLAD, and D-serine is known to inhibit non-canonical NMDARs that are linked to human problem drinking (26, 94, 147). Taken together, these findings show that the specificity of a given possible pharmacotherapy to CLAD or AOD will depend on the compound tested as well as the dose used. Interestingly, α1 AR modulation with prazosin impacts both CLAD and AOD, but does not reduce sweet fluid intake. Thus, α1 AR modulating drugs have the potential to be valuable therapeutics and likely produce different impacts on behavior depending on an individual's motivational state (including compulsion-like drinking). Said another way, these drugs have the potential to demonstrate more robustly the presence of sex and individual differences in motivation to drink.
When searching for new therapeutics for drinking problems, it is valuable if a compound is already FDA approved, since it could be more readily repurposed to address alcohol treatment. Prazosin and D-serine (and related modulators) are FDA approved. Interestingly, the so-called beta blockers (for example, the FDA-approved non-selective β adrenergic receptor inhibitor propranolol) have received much less recent attention for alcohol (128, 129). Early studies found efficacy of propranolol against mood disruptions during alcohol withdrawal (128, 148–151), while propranolol has been understudied in recent times [(128, 129, 152, 153), but see Mahabir et al. (154)].
We recently showed (126) that systemic administration of propranolol in male rats decreased CLAD or AOD in a dose dependent manner. While the low dose (2.5 mg/kg) had no effect, the middle dose (5 mg/kg) impacted CLAD more than AOD, and the higher dose (10 mg/kg) reduced both AOD and CLAD. In addition, the β1 adrenergic receptors antagonist betaxolol (BTX) affected CLAD at a lower dose (2.5 mg/kg) while the β2 adrenergic receptors antagonist ICI 118,551 had no effect, suggesting that propranolol is more selectively reducing CLAD than AOD through β1 adrenergic receptors. Interestingly, and different from prazosin, the administration of propranolol into the AIC or medial prefrontal cortex (1–10 μg) had no effects on AOD or CLAD, although there was a trend on the decreasing of CLAD when BTX was injected into AIC. Thus, brain regions where β adrenergic receptors modulators regulate CLAD are worthy of further study.
To better understand how adrenergic receptors promote similar or different aspects of alcohol drinking, one strategy we have used is to test the impact of a given drug on AOD and CLAD within the same animal. For example, one might imagine that some rats have alcohol drinking that is more driven overall by α1 adrenergic receptors, where one would predict that prazosin would cause a large drop in consumption level in both AOD and CLAD. Other rats, with lower α1 adrenergic receptor mediated drive for alcohol, would have little prazosin effects for either drinking condition. However, what we found was very different. Indeed, the prazosin reduction in AOD was not correlated with the prazosin reduction in CLAD, and this was observed for prazosin systemically or within the AIC (127). This is part of the reason (described above) that we speculate there are separable pathways within the AIC for CLAD (which we had expected) and AOD (which was unexpected). Interestingly, we found a similar pattern for β adrenergic receptors modulation (10 mg/kg propranolol), where propranolol reduction of AOD was not correlated with propranolol reduction of CLAD (126). This suggests that two different noradrenergic receptors could both be acting on AOD through different cellular mechanisms than their effects on CLAD. In an interesting convergence, a recent human study (155) used intravenous self-administration in heavy human drinkers to compare two drinking conditions, (1) free choice alcohol drinking, and (2) working for alcohol, where one has to respond more and more across the session to get alcohol (progressive ratio). Remarkably, this study found no relationship between the level of free alcohol and level of working for alcohol across subjects. This is quite similar to the putative disconnection in underlying mechanisms between AOD and CLAD. Thus, it is interesting that people working for alcohol report craving and not enjoying alcohol, while people with free alcohol report enjoying and not craving (and even though total alcohol intake was comparable). Also, more working for alcohol relates to greater family risk of AUD and also some disinhibition measures. While not measures of compulsion, such findings provide some support for the idea of distinct mechanisms for pathological intake and for easier, alcohol-only intake in heavy drinking humans.
In addition to comparing drug effects in AOD vs. CLAD, we are also interested in understanding whether the ability of a particular drug to reduce alcohol drinking is related to the basal level of intake. In other words, it is possible that heavier drinkers recruit different brain mechanisms than more moderate drinkers. Strikingly, we find that the lowest dose of prazosin (0.75 mg/kg) reduces CLAD more in rats with higher basal intake (127), which we also observed with the middle dose of propranolol (5 mg/kg) (126). Thus, α1 and β adrenergic receptor blockers may be more effective at reducing alcohol consumption in higher drinkers, and, in many ways, this is a highly important population to target, since alcohol binging humans account for most of the costs of AUD (see Introduction). Interestingly, we found a similar pattern, with greater reduction in drinking in individuals with higher basal intake, for both the Ox1R blocker (mediated through the nucleus accumbens) (156), and for a novel method to modulate NMDARs (combining D-serine with the FDA-approved sodium benzoate to reduce the breakdown of D-serine) (94). Finally, across our adrenergic receptor studies, we have observed some evidence of U-shaped effects, which are known to occur with noradrenergic signaling [see Valentino and Van Bockstaele (157); detailed in De Oliveira Sergio et al. (126)].
Finally, and importantly, our findings also showed that the combination of sub-therapeutic doses of prazosin and propranolol decreased CLAD and AOD (126); importantly, combined low-dose prazosin and propranolol reduced drinking more in individuals with higher basal alcohol intake. We had shown before that the combination of lower doses D-serine and sodium benzoate decreases CLAD, with no effect on AOD (94). The combination of low dose of these compounds is an interesting strategy since it can decrease the chances of undesirable side effects of higher doses of each drug when given alone [as detailed in De Oliveira Sergio et al. (126)].
5. Conclusion
Compulsive drives for alcohol drinking remain a major obstacle for AUD treatment. Animal models of consequence-resistant responding for alcohol can be very useful for understanding the neurobiology related to alcohol consumption as well as to help identify new pharmacological agents for AUD. The two adverse stimuli most used in rodents are quinine-adulteration and footshock-resistance, and we have outlined several advantages of the quinine-adulteration model. Using quinine-adulteration, we find that compounds such Ox1R blockers (at lower doses), NMDARs modulators, and the α1 and β adrenergic receptor antagonists decrease CLAD in rodents. We address our more recent studies where the α1 adrenergic receptor antagonist prazosin also decreases AOD, while a moderate dose of the β adrenergic receptor antagonist propranolol preferentially affected CLAD. We also highlight novel pharmacotherapy strategies which combine lower doses of FDA-approved compounds to target alcohol intake. With the quite limited treatment options available for AUD (17, 18), the significant and critical unmet need for novel therapies (especially FDA-approved drugs that could be quickly repurposed), and the findings outlined above, we have thus demonstrated the need for new clinical therapeutic interventions and highlighted the importance of animal models of compulsion for AUD.
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
Funding from National Institutes of Health (AA024109, FH).
Acknowledgments
Thanks to Molly Sazer-Hopf for assistance with Figure 2.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Footnotes
References
1. CDC Excessive Drinking Costs U.S. $223.5 Billion. Atlanta, GA: Center for Disease Control (2014).
2. Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. (2019) 394:781–92. doi: 10.1016/S0140-6736(19)31775-1
3. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharm. (2010) 35:217–38. doi: 10.1038/npp.2009.110
4. Koob GF. Negative reinforcement in drug addiction: the darkness within. Curr Opin Neurobiol. (2013) 23:559–63. doi: 10.1016/j.conb.2013.03.011
5. Bouchery EE, Harwood HJ, Sacks JJ, Simon CJ, Brewer RD. Economic costs of excessive alcohol consumption in the U .S., 2006. Am J Prev Med. (2011) 41:516–24. doi: 10.1016/j.amepre.2011.06.045
6. Sacks JJ, Roeber J, Bouchery EE, Gonzales K, Chaloupka FJ, Brewer RD. State costs of excessive alcohol consumption, 2006. Am J Prev Med. (2013) 45:474–85. doi: 10.1016/j.amepre.2013.06.004
7. Aslam A, Kwo PY. Epidemiology and disease burden of alcohol associated liver disease. J Clin Exp Hepatol. (2023) 13:88–102. doi: 10.1016/j.jceh.2022.09.001
8. Manthey J, Hassan SA, Carr S, Kilian C, Kuitunen-Paul S, Rehm J. What are the economic costs to society attributable to alcohol use? A systematic review and modelling study. Pharmacoeconomics. (2021) 39:809–22. doi: 10.1007/s40273-021-01031-8
9. Dawson DA, Grant BF, Li TK. Quantifying the risks associated with exceeding recommended drinking limits. Alcohol Clin Exp Res. (2005) 29:902–8. doi: 10.1097/01.ALC.0000164544.45746.A7
10. Moos RH, Moos BS. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction. (2006) 101:212–22. doi: 10.1111/j.1360-0443.2006.01310.x
11. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. (2009) 373:2223–33. doi: 10.1016/S0140-6736(09)60746-7
12. van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. (2015) 29:655–60. doi: 10.1177/0269881115581980
13. Esser MB, Leung G, Sherk A, Bohm MK, Liu Y, Lu H, et al. Estimated deaths attributable to excessive alcohol use among US adults aged 20 to 64 years, 2015 to 2019. JAMA Netw Open. (2022) 5:e2239485. doi: 10.1001/jamanetworkopen.2022.39485
14. Pollard CA, Morran MP, Nestor-Kalinoski AL. The COVID-19 pandemic: a global health crisis. Physiol Genomics. (2020) 52:549–57. doi: 10.1152/physiolgenomics.00089.2020
15. Mallet J, Dubertret C, Le Strat Y. Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. (2021) 106:110070. doi: 10.1016/j.pnpbp.2020.110070
16. Da BL, Im GY, Schiano TD. Coronavirus disease 2019 hangover: a rising tide of alcohol use disorder and alcohol-associated liver disease. Hepatology. (2020) 72:1102–8. doi: 10.1002/hep.31307
17. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. (2018) 320:815–24. doi: 10.1001/jama.2018.11406
18. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol Rev. (2009) 89:649–705. doi: 10.1152/physrev.00013.2008
19. Larimer ME, Palmer RS, Marlatt GA. Relapse prevention. An overview of Marlatt's cognitive-behavioral model. Alcohol Res Health. (1999) 23:151–60.
20. Anton RF. Obsessive-compulsive aspects of craving: development of the obsessive compulsive drinking scale. Addiction. (2000) 95:S211–7. doi: 10.1080/09652140050111771
21. Sinha R. Modeling stress and drug craving in the laboratory: implications for addiction treatment development. Addict Biol. (2009) 14:84–98. doi: 10.1111/j.1369-1600.2008.00134.x
22. Tiffany ST, Conklin CA. A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction. (2000) 95:S145–53. doi: 10.1080/09652140050111717
23. Epstein DH, Kowalczyk WJ. Compulsive seekers: our take. two clinicians' perspective on a new animal model of addiction. Neuropsychopharmacology. (2017). doi: 10.1038/npp.2017.132
24. Giuliano C, Peña-Oliver Y, Goodlett CR, Cardinal RN, Robbins TW, Bullmore ET, et al. Evidence for a long-lasting compulsive alcohol seeking phenotype in rats. Neuropsychopharmacology. (2018) 43:728–38. doi: 10.1038/npp.2017.105
25. Everitt BJ, Robbins TW. Drug Addiction: updating actions to habits to compulsions 10 years on. Annu Rev Psychol. (2016) 67:23–50. doi: 10.1146/annurev-psych-122414-033457
26. Hopf FW. Do specific NMDA receptor subunits act as gateways for addictive behaviors? Genes Brain Behav. (2017) 16:118–38. doi: 10.1111/gbb.12348
27. Hopf FW, Lesscher HM. Rodent models for compulsive alcohol intake. Alcohol. (2014) 48:253–64. doi: 10.1016/j.alcohol.2014.03.001
28. Guinle MIB, Sinha R. The role of stress, trauma, and negative affect in alcohol misuse and alcohol use disorder in women. Alcohol Res. (2020) 40:05. doi: 10.35946/arcr.v40.2.05
29. Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the united states, 2001–2002 to 2012–2013: results from the national epidemiologic survey on alcohol and related conditions. JAMA Psych. (2017) 74:911–23. doi: 10.1001/jamapsychiatry.2017.2161
30. White A, Castle IJP, Chen CM, Shirley M, Roach D, Hingson R. Converging patterns of alcohol use and related outcomes among females and males in the United States, 2002 to 2012. Alcohol Clin Exp Res. (2015) 39:1712–26. doi: 10.1111/acer.12815
31. Erol A, Karpyak VM. Sex and gender-related differences in alcohol use and its consequences: Contemporary knowledge and future research considerations. Drug Alcohol Depend. (2015) 156:1–13. doi: 10.1016/j.drugalcdep.2015.08.023
32. Brady KT, Randall CL. Gender differences in substance use disorders. Psychiatr Clin North Am. (1999) 22:241–52. doi: 10.1016/S0193-953X(05)70074-5
33. Becker JB, Koob GF. Sex differences in animal models: focus on addiction. Pharmacol Rev. (2016) 68:242–63. doi: 10.1124/pr.115.011163
34. Puddephatt JA, Irizar P, Jones A, Gage SH, Goodwin L. Associations of common mental disorder with alcohol use in the adult general population: a systematic review and meta-analysis. Addiction. (2021). doi: 10.1111/add.15735
35. Bloch S, Holleran KM, Kash TL, Vazey EM, Rinker JA, Lebonville CL, et al. Assessing negative affect in mice during abstinence from alcohol drinking: Limitations and future challenges. Alcohol. (2022) 100:41–56. doi: 10.1016/j.alcohol.2022.02.001
36. Logrip ML, Milivojevic V, Bertholomey ML, Torregrossa MM. Sexual dimorphism in the neural impact of stress and alcohol. Alcohol. (2018) 72:49–59. doi: 10.1016/j.alcohol.2018.02.002
37. Becker JB, Chartoff E. Sex differences in neural mechanisms mediating reward and addiction. Neuropsychopharm. (2019) 44:166–83. doi: 10.1038/s41386-018-0125-6
38. Becker JB, McClellan ML, Reed BG. Sex differences, gender and addiction. J Neurosci Res. (2017) 95:136–47. doi: 10.1002/jnr.23963
39. Grodin EN, Bujarski S, Venegas A. Reward, relief, and habit drinking: initial validation of a brief assessment tool. Alcohol Alcohol. (2019) 54:574–83. doi: 10.1093/alcalc/agz075
40. Mann K, Roos CR, Hoffmann S, Nakovics H, Leménager T, Heinz A, et al. Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. Neuropsychopharmacology. (2018) 43:891–9. doi: 10.1038/npp.2017.282
41. Leganes-Fonteneau M, Buckman J, Pawlak A, Vaschillo B, Vaschillo E, Bates M. Interoceptive signaling in alcohol cognitive biases: role of family history and alliesthetic components. Addict Biol. (2021) 26:e12952. doi: 10.1111/adb.12952
42. Nikolova YS, Knodt AR, Radtke SR, Hariri AR. Divergent responses of the amygdala and ventral striatum predict stress-related problem drinking in young adults: possible differential markers of affective and impulsive pathways of risk for alcohol use disorder. Mol Psychiatry. (2016) 21:348–56. doi: 10.1038/mp.2015.85
43. Altemus M, Sarvaiya N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. Front Neuroendocrinol. (2014) 35:320–30. doi: 10.1016/j.yfrne.2014.05.004
44. Palanza P, Parmigiani S. How does sex matter? Behavior, stress and animal models of neurobehavioral disorders. Neurosci Biobehav Rev. (2017) 76:134–43. doi: 10.1016/j.neubiorev.2017.01.037
45. Shansky RM. Sex differences in behavioral strategies: avoiding interpretational pitfalls. Curr Opin Neurobiol. (2018) 49:95–8. doi: 10.1016/j.conb.2018.01.007
46. Rincon-Cortes M, Herman JP, Lupien S. Stress: Influence of sex, reproductive status and gender. Neurobiol Stress. (2019) 10:100155. doi: 10.1016/j.ynstr.2019.100155
47. Filkowski MM, Olsen RM, Duda B, Wanger TJ, Sabatinelli D. Sex differences in emotional perception: meta analysis of divergent activation. Neuroimage. (2017) 147:925–33. doi: 10.1016/j.neuroimage.2016.12.016
48. Bangasser DA, Wicks B. Sex-specific mechanisms for responding to stress. J Neurosci Res. (2017) 95:75–82. doi: 10.1002/jnr.23812
49. Flores-Bonilla A, Richardson HN. Sex differences in the neurobiology of alcohol use disorder. Alcohol Res. (2020) 40:04. doi: 10.35946/arcr.v40.2.04
50. Myrick H, Anton RF, Li X, Henderson S, Drobes D, Voronin K, et al. Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology. (2004) 29:393–402. doi: 10.1038/sj.npp.1300295
51. Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol. (2013) 18:121–33. doi: 10.1111/j.1369-1600.2012.00464.x
52. Cofresí RU, Kohen CB, Motschman CA, Wiers RW, Piasecki TM, Bartholow BD. Behavioral response bias and event-related brain potentials implicate elevated incentive salience attribution to alcohol cues in emerging adults with lower sensitivity to alcohol. Addiction. (2022) 117:892–904. doi: 10.1111/add.15728
53. Heitmann J, van Hemel-Ruiter ME, Huisman M, Ostafin BD, Wiers RW, MacLeod C, et al. Effectiveness of attentional bias modification training as add-on to regular treatment in alcohol and cannabis use disorder: a multicenter randomized control trial. PLoS ONE. (2021) 16:e0252494. doi: 10.1371/journal.pone.0252494
54. Weafer J, Gorka SM, Dzemidzic M, Kareken DA, Phan KL, de Wit H. Neural correlates of inhibitory control are associated with stimulant-like effects of alcohol. Neuropsychopharmacology. (2021) 6:1442–50. doi: 10.1038/s41386-021-01014-5
55. Voon V, Derbyshire K, Rück C, Irvine MA, Worbe Y, Enander J, et al. Disorders of compulsivity: a common bias towards learning habits. Mol Psychiatry. (2015) 20:345–52. doi: 10.1038/mp.2014.44
56. Ersche KD, Lim TV, Ward LHE, Robbins TW, Stochl J. Creature of habit: a self-report measure of habitual routines and automatic tendencies in everyday life. Pers Individ Dif. (2017) 116:73–85. doi: 10.1016/j.paid.2017.04.024
57. Perry AN, Westenbroek C, Becker JB. The development of a preference for cocaine over food identifies individual rats with addiction-like behaviors. PLoS ONE. (2013) 8:e79465. doi: 10.1371/journal.pone.0079465
58. Naqvi NH, Bechara A. The insula and drug addiction: an interoceptive view of pleasure, urges, and decision-making. Brain Struct Funct. (2010) 214:435–50. doi: 10.1007/s00429-010-0268-7
59. George O, Ahmed SH, Gilpin NW. Are we compulsively chasing rainbows? Neuropsychopharmacology. (2022) 47:2013–5. doi: 10.1038/s41386-022-01419-w
60. Muela I, Navas JF, Ventura-Lucena JM, Perales JC. How to pin a compulsive behavior down: A systematic review and conceptual synthesis of compulsivity-sensitive items in measures of behavioral addiction. Addict Behav. (2022) 134:107410. doi: 10.1016/j.addbeh.2022.107410
61. Varona MN, Muela A, Machimbarrena JM. Problematic use or addiction? A scoping review on conceptual and operational definitions of negative social networking sites use in adolescents. Addict Behav. (2022) 134:107400. doi: 10.1016/j.addbeh.2022.107400
62. Lee RSC, Hoppenbrouwers S, Franken I. A systematic meta-review of impulsivity and compulsivity in addictive behaviors. Neuropsychol Rev. (2019) 29:14–26. doi: 10.1007/s11065-019-09402-x
63. Liu C, Rotaru K, Chamberlain SR. Distress-driven impulsivity interacts with trait compulsivity in association with problematic drinking: a two-sample study. Front Psychiatry. (2022) 13:938275. doi: 10.3389/fpsyt.2022.938275
64. Starski P, Maulucci D, Mead H, Hopf F. Adaptation of the 5-choice serial reaction time task to measure engagement and motivation for alcohol in mice. Front Behav Neurosci. (2022) 16:968359. doi: 10.3389/fnbeh.2022.968359
65. Radke AK, Sneddon EA, Frasier RM, Hopf FW. Recent perspectives on sex differences in compulsion-like and binge alcohol drinking. Int J Mol Sci. (2021) 22:3788. doi: 10.3390/ijms22073788
66. Centanni SW, Janes AC, Haggerty DL, Atwood B, Hopf FW. Better living through understanding the insula: why subregions can make all the difference. Neuropharmacology. (2021) 198:108765. doi: 10.1016/j.neuropharm.2021.108765
67. Darevsky D, Gill TM, Vitale KR, Hu B, Wegner SA, Hopf FW. Drinking despite adversity: behavioral evidence for a head down and push strategy of conflict-resistant alcohol drinking in rats. Addict Biol. (2019) 24:426–37. doi: 10.1111/adb.12608
68. Darevsky D, Hopf FW. Behavioral indicators of succeeding and failing under higher-challenge compulsion-like alcohol drinking in rat. Behav Brain Res. (2020) 393:112768. doi: 10.1016/j.bbr.2020.112768
69. De Oliveira Sergio T, Darevsky D, de Paula Soares V, de Cassia Albino M, Maulucci D, Wean S, et al. Evidence for different greater-persistence strategies under lower and higher challenge for alcohol in female rats. Biorxiv. (2022) 22–5. doi: 10.1101/2022.05.18.492488v1
70. Starski PA, Morningstar MD, Katner S, Frasier R, De Oliveira Sergio T, Wean S, et al. Anterior insular cortex firing links initial and sustained encoding during aversion-resistant alcohol consumption. Biorxiv. (2022) 2022:22–5. doi: 10.1101/2022.05.24.493243v1
71. Hogarth L. Addiction is driven by excessive goal-directed drug choice under negative affect: translational critique of habit and compulsion theory. Neuropsychopharmacology. (2020) 45:720–35. doi: 10.1038/s41386-020-0600-8
72. Yucel M, Oldenhof E, Ahmed SH. A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study. Addiction. (2019) 114:1095–109. doi: 10.1111/add.14424
73. Boness CL, Watts AL, Moeller KN, Sher KJ. The etiologic, theory-based, ontogenetic hierarchical framework of alcohol use disorder: a translational systematic review of reviews. Psychol Bull. (2021) 147:1075–123. doi: 10.1037/bul0000333
74. Pickard H. What we're not talking about when we talk about addiction. Hastings Cent Rep. (2020) 50:37–46. doi: 10.1002/hast.1172
75. Vonasch AJ, Clark CJ, Lau S. Ordinary people associate addiction with loss of free will. Addict Behav Rep. (2017) 5:56–66. doi: 10.1016/j.abrep.2017.01.002
76. Deroche-Gamonet V, Belin D. Piazza PV. Evidence for addiction-like behavior in the rat. Science. (2004) 305:1014–7. doi: 10.1126/science.1099020
77. Sommer WH, Canals S, Bifone A. From a systems view to spotting a hidden island: a narrative review implicating insula function in alcoholism. Neuropharmacology. (2022) 209:108989. doi: 10.1016/j.neuropharm.2022.108989
78. Flook EA, Luchsinger JR, Silveri MM, Winder DG, Benningfield MM, Blackford JU. Anxiety during abstinence from alcohol: a systematic review of rodent and human evidence for the anterior insula's role in the abstinence network. Addict Biol. (2021) 26:e12861. doi: 10.1111/adb.12861
79. Lovelock DF, Tyler RE, Besheer J. Interoception and alcohol: mechanisms, networks, and implications. Neuropharmacology. (2021) 3:108807. doi: 10.1016/j.neuropharm.2021.108807
81. Sridharan D, Levitin DJ, Menon V. A critical role for the right fronto-insular cortex in switching between central-executive and default-mode networks. Proc Natl Acad Sci U S A. (2008) 105:12569–74. doi: 10.1073/pnas.0800005105
82. Menon V, Uddin LQ. Saliency, switching, attention and control: a network model of insula function.Brain Struct Funct. (2010) 214:655–67. doi: 10.1007/s00429-010-0262-0
83. Seif T, Chang SJ, Simms JA, Gibb SL, Dadgar J, Chen BT, et al. Cortical activation of accumbens hyperpolarization-active NMDARs mediates aversion-resistant alcohol intake. Nat Neurosci. (2013) 16:1094–100. doi: 10.1038/nn.3445
84. Grodin EN, Sussman L, Sundby K, Brennan GM, Diazgranados N, Heilig M, et al. Neural correlates of compulsive alcohol seeking in heavy drinkers. Biol Psych Cogn Neuro Neuroimag. (2018) 2:1022–31. doi: 10.1016/j.bpsc.2018.06.009
85. Arcurio LR, Finn PR, James TW. Neural mechanisms of high-risk decisions-to-drink in alcohol-dependent women. Addict Biol. (2015) 20:390–406. doi: 10.1111/adb.12121
86. Domi E, Xu L, Toivainen S. A neural substrate of compulsive alcohol use. Sci Adv. (2021) 7:9045. doi: 10.1126/sciadv.abg9045
87. Harada M, Pascoli V, Hiver A, Flakowski J, Lüscher C. Corticostriatal activity driving compulsive reward seeking. Biol Psychiatry. (2021) 90:808–18. doi: 10.1016/j.biopsych.2021.08.018
88. Luscher C, Robbins TW, Everitt BJ. The transition to compulsion in addiction. Nat Rev Neurosci. (2020) 21:247–63. doi: 10.1038/s41583-020-0289-z
89. Simmler LD, Li Y, Hadjas LC, Hiver A, van Zessen R, Lüscher C. Dual action of ketamine confines addiction liability. Nature. (2022) 608:368–73. doi: 10.1038/s41586-022-04993-7
90. Koob GF. Neurocircuitry of alcohol addiction: synthesis from animal models. Handb Clin Neurol. (2014) 125:33–54. doi: 10.1016/B978-0-444-62619-6.00003-3
91. Chen NM, Lasek AM. Perineuronal nets in the insula regulate aversion-resistant alcohol drinking. Addict Biol Epub ahead of print. (2019). doi: 10.1101/504571
92. Campbell EJ, Flanagan JPM, Walker LC, Hill MKRI, Marchant NJ, Lawrence AJ. Anterior insular cortex is critical for the propensity to relapse following punishment-imposed abstinence of alcohol seeking. J Neurosci. (2019) 39:1077–87. doi: 10.1523/JNEUROSCI.1596-18.2018
93. Augier E, Barbier E, Dulman RS. A molecular mechanism for choosing alcohol over an alternative reward. Science. (2018) 360:1321–6. doi: 10.1126/science.aao1157
94. Wegner SA, Hu B, De Oliveira Sergio T. A novel NMDA receptor-based intervention to suppress compulsion-like alcohol drinking. Neuropharmacology. (2019) 157:107681. doi: 10.1016/j.neuropharm.2019.107681
95. Sneddon EA, Schuh KM, Fennell KA, Grahame NJ, Radke AK. Crossed high alcohol preferring mice exhibit aversion-resistant responding for alcohol with quinine but not footshock punishment. Alcohol. (2022) 105:35–42. doi: 10.1016/j.alcohol.2022.09.006
96. Simms JA, Steensland P, Medina B, Abernathy KE, Chandler LJ, Wise R, et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. Alcohol Clin Exp Res. (2008) 32:1816–23. doi: 10.1111/j.1530-0277.2008.00753.x
97. Steensland P, Fredriksson I, Holst S. The monoamine stabilizer. (-)-OSU6162 attenuates voluntary ethanol intake and ethanol-induced dopamine output in nucleus accumbens. Biol Psychiatry. (2012) 72:823–31. doi: 10.1016/j.biopsych.2012.06.018
98. Li J, Bian W, Dave V, Ye JH. Blockade of GABA(A) receptors in the paraventricular nucleus of the hypothalamus attenuates voluntary ethanol intake and activates the hypothalamic-pituitary-adrenocortical axis. Addict Biol. (2011) 16:600–14. doi: 10.1111/j.1369-1600.2011.00344.x
99. Salling MC, Skelly MJ, Avegno E, Regan S, Zeric T, Nichols E, et al. Alcohol consumption during adolescence in a mouse model of binge drinking alters the intrinsic excitability and function of the prefrontal cortex through a reduction in the hyperpolarization-activated cation current. J Neurosci. (2018) 38:6207–22. doi: 10.1523/JNEUROSCI.0550-18.2018
100. Jeanblanc J, Sauton P, Jeanblanc V, Legastelois R, Echeverry-Alzate V, Lebourgeois S, et al. Face validity of a pre-clinical model of operant binge drinking: just a question of speed. Addict Biol. (2019) 24:664–75. doi: 10.1111/adb.12631
101. Cooper A, Barnea-Ygael N, Levy D. A conflict rat model of cue-induced relapse to cocaine seeking. Psychopharmacology. (2007) 194:117–25. doi: 10.1007/s00213-007-0827-7
102. Barnea-Ygael N, Yadid G, Yaka R. Cue-induced reinstatement of cocaine seeking in the rat “conflict model”: effect of prolonged home-cage confinement. Psychopharmacology. (2012) 219:875–83. doi: 10.1007/s00213-011-2416-z
103. Sneddon EA, White RD, Radke AK. Sex differences in binge-like and aversion-resistant alcohol drinking in C57BL/6J mice. Alcohol Clin Exp Res. (2019) 43:243–9. doi: 10.1111/acer.13923
104. Katner SN, Sentir AM, Steagall KB, Ding ZM, Wetherill L, Hopf FW, et al. Modeling aversion resistant alcohol intake in indiana alcohol-preferring. Rats Brain Sci. (2022) 12:1042. doi: 10.3390/brainsci12081042
105. Kaplan JM, Baird JP, Grill HJ. Dissociation of licking and volume intake controls in rats ingesting glucose and maltodextrin. Behav Neurosci. (2001) 115:188–95. doi: 10.1037/0735-7044.115.1.188
106. Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol. (2006) 11:2–38. doi: 10.1111/j.1369-1600.2006.00012.x
107. Meinhardt MW, Sommer WH. Post-dependent state in rats as a model for medication development in alcoholism. Addict Biol. (2015) 20:1–21. doi: 10.1111/adb.12187
108. Hopf FW, Chang SJ, Sparta DR, Bowers MS, Bonci A. Motivation for alcohol becomes resistant to quinine adulteration after 3 to 4 months of intermittent alcohol self-administration. Alcohol Clin Exp Res. (2010) 34:1565–73. doi: 10.1111/j.1530-0277.2010.01241.x
109. Seif T, Simms JA, Lei K. D-serine and D-cycloserine reduce compulsive alcohol intake in rats. Neuropsychopharm. (2015) 40:2357–67. doi: 10.1038/npp.2015.84
110. Spoelder M, Hesseling P, Baars AM, Klooster JGL-v, Rotte MD, Vanderschuren LJMJ, et al. Individual variation in alcohol intake predicts reinforcement, motivation, and compulsive alcohol use in rats. Alcohol Clin Exp Res. (2015) 39:2427–37. doi: 10.1111/acer.12891
111. Spoelder M, Pol S, Janssen BSG, Baars AM, Vanderschuren LJMJ, Lesscher HMB. Loss of control over alcohol seeking in rats depends on individual vulnerability and duration of alcohol consumption experience. Behav Pharmacol. (2017) 28:334–44. doi: 10.1097/FBP.0000000000000304
112. Loi B, Lobina C, Maccioni P, Fantini N, Carai MAM, Gessa GL, et al. Increase in alcohol intake, reduced flexibility of alcohol drinking, and evidence of signs of alcohol intoxication in Sardinian alcohol-preferring rats exposed to intermittent access to 20% alcohol. Alcohol Clin Exp Res. (2010) 34:2147–54. doi: 10.1111/j.1530-0277.2010.01311.x
113. Lei K, Wegner SA, Yu JH. A single alcohol drinking session is sufficient to enable subsequent aversion-resistant consumption in mice. Alcohol. (2016) 55:9–16. doi: 10.1016/j.alcohol.2016.07.008
114. Lesscher HM, van Kerkhof LW, Vanderschuren LJ. Inflexible and indifferent alcohol drinking in male mice. Alcohol Clin Exp Res. (2010) 34:1219–25. doi: 10.1111/j.1530-0277.2010.01199.x
115. Timme NM, Ma B, Linsenbardt D, Cornwell E, Galbari T, Lapish CC. Compulsive alcohol drinking in rodents is associated with altered representations of behavioral control and seeking in dorsal medial prefrontal cortex. Nat Commun. (2022) 13:3990. doi: 10.1038/s41467-022-31731-4
116. Timme NM, Linsenbardt D, Timm M. Alcohol-preferring P rats exhibit aversion-resistant drinking of alcohol adulterated with quinine. Alcohol. (2020) 83:47–56. doi: 10.1016/j.alcohol.2019.09.003
117. Turyabahika-Thyen K, Wolffgramm J. Loss of flexibility in alcohol-taking rats: promoting factors. Eur Addict Res. (2006) 12:210–21. doi: 10.1159/000094423
118. Pelloux Y, Murray JE, Everitt BJ. Differential roles of the prefrontal cortical subregions and basolateral amygdala in compulsive cocaine seeking and relapse after voluntary abstinence in rats. Eur J Neurosci. (2013) 38:3018–26. doi: 10.1111/ejn.12289
119. Sneddon EA, Ramsey OR, Thomas A, Radke AK. Increased responding for alcohol and resistance to aversion in female mice. Alcohol Clin Exp Res. (2020) 44:1400–9. doi: 10.1111/acer.14384
120. Segal D, Valyear MD, Chaudhri N. The role of context on responding to an alcohol-predictive cue in female and male rats. Alcohol. (2022) 99:70–81. doi: 10.1016/j.alcohol.2021.10.004
121. De Oliveira Sergio T, Wetherill L, Kwok C, Khoyloo F, Hopf FW. Sex differences in specific aspects of two animal tests of anxiety-like behavior. Psychopharmacology. (2021) 238:2775–87. doi: 10.1007/s00213-021-05893-w
122. Olvera-Hernandez S, Fernandez-Guasti A. Sex differences in the burying behavior test in middle-aged rats: effects of diazepam. Pharmacol Biochem Behav. (2011) 99:532–9. doi: 10.1016/j.pbb.2011.05.030
123. Shepherd JK, Flores T, Rodgers RJ, Blanchard RJ, Blanchard DC. The anxiety/defense test battery: influence of gender and ritanserin treatment on antipredator defensive behavior. Physiol Behav. (1992) 51:277–85. doi: 10.1016/0031-9384(92)90141-N
124. Kwok C, Lei K, Pedrozo V, Anderson L, Ghotra S, Walsh M, et al. Differential importance of nucleus accumbens Ox1Rs and AMPARs for female and male mouse binge alcohol drinking. Sci Rep. (2021) 11:231. doi: 10.1038/s41598-020-79935-2
125. Hopf FW, Mangieri RA. Do Alcohol-related AMPA-type glutamate receptor adaptations promote intake? Handb Exp Pharmacol. (2018) 248:157–86. doi: 10.1007/164_2018_105
126. De Oliveira Sergio T, Wean S, Katner S, Hopf F. The role of beta- and alpha-adrenergic receptors on compulsion-like alcohol drinking. Biorvix. (2022) 11: doi: 10.1101/2022.11.20.517252v1
127. De Oliveira Sergio T, Lei K, Kwok C, Ghotra S, Wegner SA, Walsh M, et al. The role of Anterior Insula-brainstem projections and alpha-1 noradrenergic receptors for compulsion-like and alcohol-only drinking. Neuropsychopharmacology. (2021) 35:1751–60. doi: 10.1038/s41386-021-01071-w
128. Downs AM, McElligott ZA. Noradrenergic circuits and signaling in substance use disorders. Neuropharmacology. (2022) 208:108997. doi: 10.1016/j.neuropharm.2022.108997
129. Vazey EM, den Hartog CR, Moorman DE. Central Noradrenergic Interactions with Alcohol and Regulation of Alcohol-Related Behaviors. Handb Exp Pharmacol. (2018) 248:239–60. doi: 10.1007/164_2018_108
130. Sinha R, Wemm S, Fogelman N, Milivojevic V, Morgan PM, Angarita GA, et al. Moderation of Prazosin's efficacy by alcohol withdrawal symptoms. Am J Psychiatry. (2021) 178:447–58. doi: 10.1176/appi.ajp.2020.20050609
131. Raskind MA, Millard SP, Petrie EC, Peterson K, Williams T, Hoff DJ, et al. Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin. Biol Psychiatry. (2016) 80:736–42. doi: 10.1016/j.biopsych.2016.03.2108
132. Haass-Koffler CL, Goodyear K, Zywiak WH, Magill M, Eltinge SE, Wallace PM, et al. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend. (2017) 177:23–8. doi: 10.1016/j.drugalcdep.2017.03.016
133. Wilcox CE, Tonigan JS, Bogenschutz MP. A Randomized, placebocontrolled, clinical trial of prazosin for the treatment of alcohol use disorder. J Addict Med. (2018) 12:339–45. doi: 10.1097/ADM.0000000000000413
134. Petrakis IL, Desai N, Gueorguieva R, Arias A, O'Brien E, Jane JS, et al. Prazosin for veterans with posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial. Alcohol Clin Exp Res. (2016) 40:178–86. doi: 10.1111/acer.12926
135. Ralevski E, Petrakis I, Altemus M. Heart rate variability in alcohol use: a review. Pharmacol Biochem Behav. (2019) 176:83–92. doi: 10.1016/j.pbb.2018.12.003
136. Fox HC, Anderson GM, Tuit K, Hansen J, Kimmerling A, Siedlarz KM, et al. Prazosin effects on stress- and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings. Alcohol Clin Exp Res. (2012) 36:351–60. doi: 10.1111/j.1530-0277.2011.01628.x
137. Milivojevic V, Angarita GA, Hermes G, Sinha R, Fox HC. Effects of Prazosin on provoked alcohol craving and autonomic and neuroendocrine response to stress in alcohol use disorder. Alcohol Clin Exp Res. (2020) 44:1488–96. doi: 10.1111/acer.14378
138. Simpson TL, Saxon AJ, Meredith CW. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence. Alcohol Clin Exp Res. (2009) 33:255–63. doi: 10.1111/j.1530-0277.2008.00807.x
139. Simpson TL, Saxon AJ, Stappenbeck C. Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry. (2018) 175:1216–24. doi: 10.1176/appi.ajp.2018.17080913
140. Sinha R, Fogelman N, Wemm S, Angarita G, Seo D, Hermes G. Alcohol withdrawal symptoms predict corticostriatal dysfunction that is reversed by prazosin treatment in alcohol use disorder. Addict Biol. (2022) 27:e13116. doi: 10.1111/adb.13116
141. Kenna GA, Haass-Koffler CL, Zywiak WH, Edwards SM, Brickley MB, Swift RM, et al. Role of the alpha1 blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial. Addict Biol. (2016) 21:904–14. doi: 10.1111/adb.12275
142. Barbier E, Barchiesi R, Domi A, Chanthongdee K, Domi E, Augier G, et al. Downregulation of synaptotagmin 1 in the prelimbic cortex drives alcohol-associated behaviors in rats. Biol Psychiatry. (2021) 89:398–406. doi: 10.1016/j.biopsych.2020.08.027
143. Lei K, Wegner SA, Yu JH. Orexin-1 receptor blockade suppresses compulsive-like alcohol drinking in mice. Neuropharmacology. (2016) 110:8. doi: 10.1016/j.neuropharm.2016.08.008
144. Anderson RI, Becker HC, Adams BL et al. Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. Front Neurosci. (2014) 8:33. doi: 10.3389/fnins.2014.00033
145. Giannotti G, Mottarlini F, Heinsbroek JA, Mandel MR, James MH, Peters J. Oxytocin and orexin systems bidirectionally regulate the ability of opioid cues to bias reward seeking. Transl Psychiatry. (2022) 12:432. doi: 10.1038/s41398-022-02161-z
146. Krishnan-Sarin S, O'Malley SS, Franco N et al. N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers. Alcohol Clin Exp Res. (2015) 39:300–7. doi: 10.1111/acer.12619
147. Bach P, Kirsch M, Hoffmann S, Jorde A, Mann K, Frank J, et al. The effects of single nucleotide polymorphisms in glutamatergic neurotransmission genes on neural response to alcohol cues and craving. Addict Biol. (2015) 20:1022–32. doi: 10.1111/adb.12291
148. Zilm DH, Sellers EM, MacLeod SM. Letter: propranolol effect on tremor in alcoholic withdrawal. Ann Intern Med. (1975) 83:234–6. doi: 10.7326/0003-4819-83-2-234
149. Carlsson C, Johansson T. The psychological effects of propranolol in the abstinence phase of chronic alcoholics. Br J Psychiatry. (1971) 119:605–6. doi: 10.1192/bjp.119.553.605
150. Horwitz RI, Gottlieb LD Kraus ML. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med. (1989) 149:1089–93. doi: 10.1001/archinte.149.5.1089
151. Bailly D, Servant D, Blandin N, Beuscart R, Parquet PJ. Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam. Biomed Pharmacother. (1992) 46:419–24. doi: 10.1016/0753-3322(92)90047-B
152. Steenen SA, van Wijk AJ, van der Heijden GJMG, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. (2016) 30:128–39. doi: 10.1177/0269881115612236
153. Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry. (2020) 11:595584. doi: 10.3389/fpsyt.2020.595584
154. Mahabir M, Ashbaugh AR, Saumier D. Propranolol's impact on cognitive performance in post-traumatic stress disorder. J Affect Disord. (2016) 192:98–103. doi: 10.1016/j.jad.2015.11.051
155. Cyders MA, Plawecki MH, Whitt ZT, Kosobud AEK, Kareken DA, Zimmermann US, et al. Translating preclinical models of alcohol seeking and consumption into the human laboratory using intravenous alcohol self-administration paradigms. Addict Biol. (2021) 26:e13016. doi: 10.1111/adb.13016
156. Lei K, Kwok C, Darevsky D, Wegner SA, Yu J, Nakayama L, et al. Nucleus accumbens shell orexin-1 receptors are critical mediators of binge intake in excessive-drinking individuals. Front Neurosci. (2019) 13:88. doi: 10.3389/fnins.2019.00088
Keywords: compulsion alcohol drinking, α adrenergic receptors, β adrenergic receptors, quinine adulteration, footshock sensitivity
Citation: De Oliveira Sergio T, Frasier RM and Hopf FW (2023) Animal models of compulsion alcohol drinking: Why we love quinine-resistant intake and what we learned from it. Front. Psychiatry 14:1116901. doi: 10.3389/fpsyt.2023.1116901
Received: 05 December 2022; Accepted: 17 February 2023;
Published: 24 March 2023.
Edited by:
Daniel da Silva, Icahn School of Medicine at Mount Sinai, United StatesReviewed by:
M. Julia Garcia-Fuster, University of the Balearic Islands, SpainKaren K. Szumlinski, University of California, Santa Barbara, United States
Copyright © 2023 De Oliveira Sergio, Frasier and Hopf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thatiane De Oliveira Sergio, tdeolive@iu.edu